Teva-Makes-Hostile-Bid-Acquire
Teva Offers to Buy Mylan for $40 Billion - WSJ
Teva Pharmaceutical Industries' quest to acquire Mylan NV could wind up in a Dutch court - Pittsburgh Business Times
Teva offers to buy Mylan in $40 billion deal | The Times of Israel
Generic EpiPen by Teva Wins FDA Nod After 2 Year Delay | Fierce Pharma
Teva's Generic EpiPen Will Cost As Much As Mylan's Generic | Time
Drugmaker Teva makes $40B bid for rival Mylan
Teva Pharmaceutical Gains Approval For Generic EpiPen, Mylan Shares Flat
Teva, Mylan, Sandoz and Aurobindo hit with patent suit
Teva's recall of U.S.-made drugs latest example of contamination fears in generic marketplace; report says Lilly, Pfizer and former Mylan plant in Morgantown have been cited in the past | WV News
Teva shares rival Mylan's pain as both hit two-year lows | Fierce Pharma
Where a Teva-Mylan Deal Would Rank Among Big Pharma Companies
Valsartan recall expands to Mylan, Teva products | Fierce Pharma
Teva Offers to acquire Mylan for $40 billion in cash, stock | Pharma Companies
Mylan Rejects Teva Buyout Offer
Federal Circuit Upholds Mylan's U.S. Patents on Perforomist® Inhalation Solution; Decision Prevents Approval of Teva ANDA
Teva, Mylan: Desperate Times Call For Desperate Measures (NYSE:TEVA) | Seeking Alpha
Mylan, Generic Copaxone Punish Teva (NYSE:TEVA) | Seeking Alpha
Mylan surges, Teva slumps after FDA approves Copaxone copy | Reuters.com
Teva, Mylan: Desperate Times Call For Desperate Measures (NYSE:TEVA) | Seeking Alpha
Lawmakers to Teva, Mylan: Stop stonewalling our price-fixing probe | Fierce Pharma
Mylan sees opportunity in rival Teva's weakness - MarketWatch
Teva's Deal for Mylan Shows Corporate Israel's M&A Hunger - WSJ
